{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:02:06Z","timestamp":1777420926603,"version":"3.51.4"},"reference-count":10,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2014,11,26]],"date-time":"2014-11-26T00:00:00Z","timestamp":1416960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2015,2]]},"abstract":"<jats:p>Ebola virus disease (EVD) poses significant clinical care implications for pharmacists. Emergency preparedness efforts should be undertaken to ensure vital response to EVD. Pharmacists should consider factors such as enhanced use of resources for front-line EVD patient care along with procurement of investigational medications. Appropriate and timely preparation, distribution, and administration of treatment for patients with EVD in the setting of substantial critical illness as well as infection control measures are essential. Aggressive supportive care and early, goal-directed therapy are cornerstones of therapy, whereas investigational treatments for EVD will likely play a larger, more well-defined role as future clinical trials are conducted.<\/jats:p>","DOI":"10.1177\/1060028014561782","type":"journal-article","created":{"date-parts":[[2014,11,26]],"date-time":"2014-11-26T22:17:53Z","timestamp":1417040273000},"page":"247-249","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Ebola Virus Disease"],"prefix":"10.1177","volume":"49","author":[{"given":"Anthony J.","family":"Guarascio","sequence":"first","affiliation":[{"name":"Mylan School of Pharmacy at Duquesne University, Pittsburgh, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew C.","family":"Faust","sequence":"additional","affiliation":[{"name":"Texas Health Presbyterian Hospital, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyndsay","family":"Sheperd","sequence":"additional","affiliation":[{"name":"Texas Health Presbyterian Hospital, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren A.","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"Mylan School of Pharmacy at Duquesne University, Pittsburgh, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2014,11,26]]},"reference":[{"key":"bibr1-1060028014561782","unstructured":"Centers for Disease Control and Prevention. Infection prevention and control recommendations for hospitalized patients with known or suspected Ebola virus disease in U.S. hospitals. http:\/\/www.cdc.gov\/vhf\/ebola\/hcp\/infection-prevention-and-control-recommendations.html. Accessed November 12, 2014."},{"key":"bibr2-1060028014561782","doi-asserted-by":"publisher","DOI":"10.1086\/520545"},{"key":"bibr3-1060028014561782","unstructured":"Centers for Disease Control and Prevention. Detailed hospital checklist for Ebola preparedness. http:\/\/www.cdc.gov\/vhf\/ebola\/pdf\/hospital-checklist-ebola-preparedness.pdf. Accessed November 12, 2014."},{"key":"bibr4-1060028014561782","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411677"},{"key":"bibr5-1060028014561782","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1300266"},{"key":"bibr6-1060028014561782","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-4453(98)80153-9"},{"key":"bibr7-1060028014561782","doi-asserted-by":"publisher","DOI":"10.1086\/514271"},{"key":"bibr8-1060028014561782","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.8.1016"},{"key":"bibr9-1060028014561782","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg007"},{"key":"bibr10-1060028014561782","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g6436"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028014561782","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028014561782","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028014561782","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:15:34Z","timestamp":1777374934000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028014561782"}},"subtitle":["Roles and Considerations for Pharmacists"],"short-title":[],"issued":{"date-parts":[[2014,11,26]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["10.1177\/1060028014561782"],"URL":"https:\/\/doi.org\/10.1177\/1060028014561782","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,26]]}}}